NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/11/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,417.98 mln
Float43.60 mln
Earnings Date11/03/2026
EPS
3.09
Solid
P / E
13.44
Fair value
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-2.79
Likely reliable
1-Year Forecast
47.36
Modest upside
Relative Strength
92
/ 100
Top performer
Business Description
Harmony Biosciences Holdings is a pharmaceutical company based in Plymouth Meeting, Pennsylvania, focused on treating rare neurological conditions. Its flagship product, WAKIX, is an approved treatment for excessive daytime sleepiness in adults with narcolepsy, while its broader pipeline targets conditions such as Prader-Willi Syndrome, Fragile X Syndrome, Dravet Syndrome, and epilepsy. The company is advancing multiple drug candidates through clinical trials, including orexin receptor agonists and other compounds aimed at sleep disorders and seizure-related conditions. Founded in 2017, Harmony Biosciences serves patients across the United States who have limited treatment options for these complex and often underserved diseases.
